Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Opgen Inc
(NQ:
OPGN
)
1.360
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 29, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Opgen Inc
OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 29, 2023
From
OpGen, Inc.
Via
Globe NewsWire
OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2022 on March 29th at 4:30 p.m. Eastern Time
March 22, 2023
From
OpGen, Inc.
Via
Globe NewsWire
OpGen Subsidiary Ares Genetics Announces its Move to New Vienna Location and Provides Update on Business Growth
March 01, 2023
From
OpGen, Inc.
Via
Globe NewsWire
OpGen Announces Exercise of All Prefunded Warrants
February 17, 2023
From
OpGen, Inc.
Via
Globe NewsWire
OpGen subsidiary Ares Genetics announces granting of key patent in China
January 26, 2023
From
OpGen, Inc.
Via
Globe NewsWire
OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update
January 18, 2023
From
OpGen, Inc.
Via
Globe NewsWire
OpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration Project
January 17, 2023
Successful delivery of milestones triggers milestone payment
From
OpGen, Inc.
Via
Globe NewsWire
OpGen Announces Closing of $7.5 Million Public Offering
January 11, 2023
From
OpGen, Inc.
Via
Globe NewsWire
OpGen Announces Pricing of $7.5 Million Public Offering
January 06, 2023
From
OpGen, Inc.
Via
Globe NewsWire
OpGen Announced 1-for-20 Reverse Stock Split
January 04, 2023
From
OpGen, Inc.
Via
Globe NewsWire
OpGen (NASDAQ: OPGN) Reports Positive Data from Clinical Trial for Unyvero as Diagnostic for UTI
December 13, 2022
OpGen, Inc. (NASDAQ: OPGN) is engaged as a precision medicine company that is focused on developing molecular diagnostics and bioinformatics
Via
Spotlight Growth
OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel
December 13, 2022
From
OpGen, Inc.
Via
Globe NewsWire
OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022
From
OpGen, Inc.
Via
Globe NewsWire
OpGen Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2022 and Provides Business Update
October 27, 2022
From
OpGen, Inc.
Via
Globe NewsWire
OpGen to Provide Business Update and Financial Results for the Third Quarter 2022 on November 10th at 4:30 p.m. Eastern Standard Time
October 27, 2022
From
OpGen, Inc.
Via
Globe NewsWire
OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support
October 25, 2022
From
OpGen, Inc.
Via
Globe NewsWire
OpGen Announces Closing of $3.38 Million Registered Direct Offering
October 03, 2022
From
OpGen, Inc.
Via
Globe NewsWire
OpGen Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel
October 03, 2022
From
OpGen, Inc.
Via
Globe NewsWire
OpGen Announces $3.38 Million Registered Direct Offering
September 30, 2022
From
OpGen, Inc.
Via
Globe NewsWire
OpGen Subsidiary Ares Genetics GmbH Enters into Collaboration Agreement with the Belgian National Reference Centre for Invasive S. pneumoniae at UZ Leuven
July 26, 2022
From
OpGen, Inc.
Via
Globe NewsWire
OpGen, Inc. (NASDAQ:OPGN) Investor Alert: Investigation over Potential Wrongdoing
February 15, 2022
San Diego, CA -- (SBWIRE) -- 02/15/2022 -- Certain directors of OpGen, Inc are under investigation concerning potential breaches of fiduciary duties.
Via
SBWire
Investigation Announced for Investors in OpGen, Inc. (NASDAQ:OPGN) Shares
December 15, 2021
San Diego, CA -- (SBWIRE) -- 12/15/2021 -- An investigation was announced for investors of OpGen, Inc. (NASDAQ:OPGN) shares over potential securities laws violations by OpGen, Inc.
Via
SBWire
NASDAQ: OPGN Investor Notice: Investigation over Potential Wrongdoing at OpGen, Inc.
November 30, 2021
San Diego, CA -- (SBWIRE) -- 11/30/2021 -- An investigation on behalf of investors in OpGen, Inc. (NASDAQ: OPGN) shares over potential wrongdoing at OpGen, Inc. was announced.
Via
SBWire
OpGen, Inc. (NASDAQ:OPGN) Investor Notice: Investigation over Possible Violations of Securities Laws
November 10, 2021
San Diego, CA -- (SBWIRE) -- 11/10/2021 -- OpGen, Inc is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.